FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Michael Singer, MD, discusses a study that investigated the durability of suprachoroidal triamcinolone acetonide for uveitic macular edema.
The study used real-world data collected from the IRIS registry and followed more than 800 patients who received suprachoroidal triamcinolone acetonide for 6 months.
“The first thing we found was that 40% of patients who were included in real-life use had a history of IOP problems or glaucoma, showing that there might be a place for this in these steroid-responsive patients,” Singer said. “The other thing we found was that 75% of people were able to go 6 months or longer without any type of steroid given as a rescue.”
Sources/Disclosures
Collapse
Singer M. An IRIS database look at triamcinolone acetonide. Presented at: Retina World Congress; May 9-12, 2024; Fort Lauderdale, Florida.
Disclosures:
Singer reports consulting for Bausch + Lomb.